- The trend backdrop is active with a 16-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
NEOGEN
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Neogen Chemicals Limited · Basic Materials · Specialty Chemicals
Latest close
2,032 INR
0.4%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 25.2% above the Trend Line and sits at 75.7% of its 52-week range. The latest completed week returned 0.4%, after a -2.6% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 50/100.
Setup score
62
out of 100
Latest Close
2,032 INR
7 Aug 2026
1W Return
0.4%
latest completed week
4W Return
-2.6%
short-term follow-through
12W Return
22.1%
quarterly tape
Trend Breadth
30.8%
16 of 52 weeks active
Volume Ratio
1.3x
vs 13-week average
- Next-week expectancy is negative at 43.73% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
0.4%
Latest completed week; four-week move -2.6%.
Indicator stack
62/71
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 43.73%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
45 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 25.2% above the Trend Line and sits at 75.7% of its 52-week range. The latest completed week returned 0.4%, after a -2.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.3x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9712-week average 0.82
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.97Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -2.6% over four weeks, 22.1% over 12 weeks, and 43.3% over one year. The current trend has remained active for 16 consecutive weeks.
Performance by holding period
Active trend streak16 weeks
Active weeks in one year16
Trend breadth30.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.20Latest activity-pressure read.
Pressure change-12.3%Four-week change in activity pressure.
Leadership35.42Latest relative-leadership reading.
RS change-22.0%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 88%
Model confidence 82%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength8/100Blend of value, momentum, and quality. Underlying universe rank 93; rank 1 is best.
Value5/100Relative valuation strength. Underlying universe rank 96; rank 1 is best.
Quality5/100Profitability and accounting quality. Underlying universe rank 96; rank 1 is best.
Momentum89/100Medium-term price momentum. Underlying universe rank 12; rank 1 is best.
Growth26/100Revenue and earnings growth. Underlying universe rank 75; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework5/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 193.8x Price divided by trailing earnings.
- Price / sales
- 6.5x Market value relative to trailing revenue.
- EV / EBITDA
- 48.4x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -11.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 45.9% Gross profit retained from each unit of revenue.
- Operating margin
- 12.7% Operating profit retained from revenue.
- Free-cash-flow margin
- -91.3% Free cash flow generated from revenue.
- Return on invested capital
- 3.7% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 12.2% Latest one-year revenue growth.
- EPS growth
- -17.5% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.0% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.1% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 9.7x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 45 relevant articles.
8 positive · 30 neutral · 7 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-14.4%Distance below the 52-week high.
13-week volatility5.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher17 of 269 weeks finished lower.
Best week+14.3%Week of 10 Apr.
Worst week-11.7%Week of 27 Mar.
Latest week+0.4%Week of 7 Aug.
Shape of recent returns
Strong gains10
Modest gains7
Flat weeks0
Modest losses3
Sharp losses6
Recent vol5.0%13-week weekly-return volatility.
Base vol6.7%52-week weekly-return volatility.
Up/down split30/22Count of positive and negative weeks in the 52-week window.
Average skew5.3% / -5.0%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Basic Materials
4-week rank- / 100
Group average2.8%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD52.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
IndustryIN Specialty Chemicals
4-week rank77 / 100
Group average5.8%
Trend breadth77.0%
Trend77.0%active weekly trend signals
MD75.0%positive activity pressure
RS72.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape63/100
Trend, activity pressure, participation, and risk combine to a 63/100 tape read.
Indicator analysis91/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.97; No reversal markers Next-Week ExpectancyNegative 43.73%Next-week expectancy is negative with a 43.73% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors23/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 4; Small Cap Core rank 91 SVQF5/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1497.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 45 relevant articles.
Medical Devices & Supplies - Diversified Stocks Q2 Results: Benchmarking Neogen (NASDAQ:NEOG) Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 2,032 INR | 0.4% | 1,624 INR | 1,603 INR | 1.20 | 35.42 | 522.9K | On |
| 31 Jul 2026 | 2,023 INR | -1.9% | 1,594 INR | 1,600 INR | 1.47 | 36.93 | 1.2M | On |
| 24 Jul 2026 | 2,063 INR | -5.2% | 1,565 INR | 1,597 INR | 1.53 | 44.17 | 380.4K | On |
| 17 Jul 2026 | 2,176 INR | 4.3% | 1,534 INR | 1,594 INR | 1.49 | 49.63 | 958.5K | On |
| 10 Jul 2026 | 2,085 INR | 5.9% | 1,498 INR | 1,590 INR | 1.37 | 45.41 | 395.8K | On |
| 3 Jul 2026 | 1,968 INR | 5.0% | 1,465 INR | 1,587 INR | 1.33 | 37.94 | 48.6K | On |
| 26 Jun 2026 | 1,875 INR | -3.0% | 1,434 INR | 1,585 INR | 1.30 | 33.33 | 0 | On |
| 19 Jun 2026 | 1,932 INR | -5.0% | 1,409 INR | 1,583 INR | 1.40 | 38.31 | 41.5K | On |
| 12 Jun 2026 | 2,034 INR | 6.8% | 1,386 INR | 1,581 INR | 1.40 | 48.83 | 196.6K | On |
| 5 Jun 2026 | 1,904 INR | 2.4% | 1,359 INR | 1,578 INR | 1.32 | 41.73 | 89.4K | On |
| 29 May 2026 | 1,858 INR | 10.1% | 1,344 INR | 1,576 INR | 1.39 | 37.99 | 626.1K | On |
| 22 May 2026 | 1,687 INR | 1.3% | 1,330 INR | 1,574 INR | 1.38 | 24.85 | 716.6K | On |
| 15 May 2026 | 1,665 INR | -6.1% | 1,323 INR | 1,573 INR | 1.46 | 23.82 | 215.0K | On |
| 8 May 2026 | 1,772 INR | 8.2% | 1,316 INR | 1,573 INR | 1.48 | 29.29 | 426.4K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.